Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment believe the medication will be effective, but have concerns about the regulatory process used to endorse the drug and are divided over whether the drug is fairly priced at $56,000 a year, according to a new survey from STAT and The Harris Poll.
The responses underscore that the Food and Drug Administration approval this month of the drug, called Aduhelm, has proven divisive among a wide array of experts, and the poll shows the same is true for the U.S. public. Among those who had only heard about the approval, slightly more than half agree the drug will be effective, but were concerned about the FDA process.
Nonetheless, the vast majority of the participants in the survey — which queried 2,105 U.S. adults between June 11 and June 13 — said they are excited by the prospect of a new treatment for Alzheimer’s disease. Of those, 1,369 said they had at least heard about the FDA approval, although half of that group — or 23% of all those surveyed — indicated they were familiar with the endorsement and the details.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
